NYSEMKT:CANF

Can-fite Biopharma Stock News

Healthcare > Biotechnology

Buy CANF

*Your capital is at risk

$3.15

-0.130 (-3.96%)

At Close: Jul 31, 2026

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

07:00am, Monday, 27'th May 2024

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addre

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

07:00am, Thursday, 23'rd May 2024

RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address o

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

07:00am, Monday, 13'th May 2024

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

09:00am, Friday, 10'th May 2024

ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Mone

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

07:00am, Monday, 06'th May 2024

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addres

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

07:00am, Thursday, 25'th Apr 2024

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

07:00am, Monday, 15'th Apr 2024

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

07:00am, Wednesday, 03'rd Apr 2024

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

07:00am, Monday, 01'st Apr 2024

Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel

Can-Fite Reports 2023 Financial Results and Clinical Update

07:00am, Thursday, 28'th Mar 2024

RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

07:00am, Monday, 11'th Mar 2024

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by